Most Common Cause Of High Platelet Count – /l It is associated with higher cancer rates. It is uncertain whether the platelet count is at the upper end of the normal range (high normal: 326-400 x 10).
Design and setting: A prospective cohort study was conducted using data from the Clinical Practice Research Datalink and the National Cancer Registry and Analysis Service, dating from 1 May 2005 to 30 April 2014.
- 1 Most Common Cause Of High Platelet Count
- 2 Making A Difference
- 3 The Role Of Platelets In Sepsis
- 4 Immune Thrombocytopenic Purpura (itp) Symptoms And Treatment
Most Common Cause Of High Platelet Count
/l Oversampling was done to maximize the accuracy of cancer incidence estimates. All patients were older than 40 years and had not been previously diagnosed with cancer. The effects of age, gender and smoking were explored. Non-melanoma skin cancers were omitted from exclusions and incidence.
Making A Difference
Results: One-year cancer incidence increased significantly with age, male sex, and platelet count elevation. The incidence of males aged ≥60 years with a high normal count was 4.2% (95% confidence interval [CI] = 4.0 to 4.4). The highest incidence of 6.7% (95% CI = 5.3 to 8.4) was found in males aged ≥80 years, who had platelets in the range of 376-400 × 10.
/to; This was 3.1 percentage points higher than the incidence rate for patients in the same age group who had lower normal counts of 150-325 x 10
/to. The risks for all female subgroups were <3%. Patients with high normal platelet counts were at highest risk of developing lung and colorectal cancer and, in general, had advanced-stage cancer at diagnosis.
Conclusion: Platelet counts in the high normal range in males aged ≥60 years may be indicative of an underlying malignancy, and referral for further investigation should be considered.
The Role Of Platelets In Sepsis
Elevated platelet count (thrombocytosis) is a newly discovered marker of cancer in primary care; The one-year incidence of cancer in patients with thrombocytosis was found to be 11.6% for males and 6.2% for females.
These figures far exceed the 3% threshold set by the National Institute for Health and Care Excellence (NICE) for investigating the incidence of cancer in the UK.
Identifying platelet counts at which patients are at ≥3% cancer risk could contribute to improving the selection of patients for further investigation in primary care and, more importantly, avoiding unnecessary investigation in those at lower risk. As such, the researchers examined cancer incidence, overall and by site, in patients with normal platelet counts, stratified by age and sex, with a particular focus on those with counts at the upper end of the normal range.
Primary care electronic medical records for this prospective cohort study were extracted from the GOLD Clinical Practice Research Database (CPRD). The CPRD contains anonymized electronic records, including all patient consultations, diagnoses and laboratory results from approximately 8% of practices in the UK. Linkage to data held by the National Cancer Registration and Analysis Service (NCRAS) was available for all patients from English practices; This provided a second mechanism for determining cancer prognosis and cancer stage at diagnosis.
Pdf) Platelet Function Tests And Inflammatory Markers For The Differentiation Of Primary Thrombocytosis And Secondary Thrombocytosis
/l was registered between May 1, 2005 and April 30, 2013; They were ≥40 years of age at the time of the platelet count; and registered in a practice with the NCRAS Cancer Registry Link. Two samples were extracted:
Cancer risk in primary care patients with thrombocythemia (elevated platelet count > 400 x 10
/l) was found in males and females approximately four times and twice above the 3% threshold for urgent investigation of suspected cancer cases set by the National Institute for Health and Care Excellence, respectively. The researchers investigated patients who had platelet counts at the upper end of the normal range (high normal: 326-400 x 10).
/l) To help determine whether cancer should be considered. It has been found that older males with a high normal platelet count have an increased incidence of cancer within one year compared to those with a well within the normal range of platelets. At the upper end of the normal range, colorectal cancer was more likely to be diagnosed in males, and therefore, in the absence of any other indicative clinical features, fecal immunohistochemical testing may be the most appropriate initial investigation. These findings support the utility of platelet counts as a guide to identifying patients who may have cancer.
Platelet Heterogeneity In Myeloproliferative Neoplasms
Patients were excluded if they were diagnosed with cancer before the index date or a subsequent cancer was detected by screening.
Sex and age at index date (categorized into 10-year ranges up to ≥80 years) were retrieved from CPRD records. Smoking status (“never” or “past/current”) was determined using reading code and product code lists (for smoking cessation treatments) published by Booth
Patient records were screened for cancer warning symptoms in the 21 days prior to their index date.
Cancer diagnoses in the year following the index date were identified by searching patients’ CPRD GOLD records for any of 2182 cancer-related read codes covering 21 specific body sites, as well as a miscellaneous category. This list of reading codes (available from the authors upon request) has been used in several previous studies. Incident diagnoses for the same period were also extracted from NCRAS data using 02 (morphology) codes from the 10th revision of the International Classification of Diseases. As is standard practice, non-melanoma skin cancers have not been studied; Since these conditions are diagnosed largely visually, identification of blood-based markers is unlikely to be clinically useful. Diagnoses recorded in the CPRD or NCRAS data were accepted, with the closest record in either designated as the date of diagnosis. Stage at diagnosis was extracted from NCRAS data, where available, and dichotomized into “early” (stages 0–2) or “advanced” (stages 3–4).
Primary Thrombocytosis In Children
To estimate a cancer incidence of 3% (NICE recommended threshold for urgent referral) with a margin of error of ≥1%, sample size calculation indicated that 1118 patients would be needed for each age/sex/platelet count subgroup. Feasibility calculations indicate that this size would be reached in all strata except males aged ≥80 years in the third group with a high normal level. Because the size of the data set is limited to 300,000 patients due to budgetary and CPRD constraints, all eligible patients in the high-normality groups were included; The remaining allocation was given to patients in the lower normal group, where an equal-sized simple random sample (SRS) was taken for each of the 10 age/sex subgroups.
One-year cancer incidence is reported as a percentage (with 95% confidence intervals [CIs]), stratified by platelet count group, age range, and sex, as well as comparator baseline cancer incidence (as determined from nationally reported incidence By NCRAS numbers. For patients in the high-normal groups, this equates to the positive predictive value (PPV) of their platelet count cancer. Incidence rate is presented by platelet count group for subgroups in which a significant increase in incidence was observed.
The most commonly diagnosed cancers were identified, as well as the proportions of patients in whom a high normal number was the first recorded feature of these cancers. Odds ratios (ORs) by platelet count group for diagnosis of these cancers, and any cancer, were obtained from logistic regressions that adjusted for age, sex, and smoking history; This used the full sample.
Another logistic regression model was constructed to investigate the relationship between high normal number and advanced stage at diagnosis, controlling for patients’ age, sex, smoking history, and site of cancer diagnosis. This model included all patients diagnosed with cancer and complete staging information.
Mayo Clinic Q And A: What Causes A High Platelet Count?
Analyzes were performed using Stata/SE (version 15.0), and results were reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.
The final sample consisted of 226,262 patients with high normal counts and 69,050 patients with lower normal counts (Figure 1). The median age of patients in the high-normal groups was 60 years (interquartile range, 47–71 years) and 158,081 (69.9%) were female. The SRS included 6995 patients in the lower normal group for each age/sex subgroup; Demographics were not reported because the methods created an artificial population.
A total of 5178 cancer cases were recorded in the data sources. In total, only 762 cases were recorded by CPRD, only 866 cases were recorded by NCRAS, and 3550 cases of cancer were reported in both. In 68,181 male patients from the high-normal groups, 1,869 cancer cases were diagnosed within 1 year (2.7%; 95% CI = 2.6 to 2.9). In contrast, among the 158,081 patients in the high-normal groups, there were 2,206 cancer cases (1.4%; 95% CI = 1.3 to 1.5). The comparable incidences for patients in the low-normal group were 2.1% (95% CI = 2.0 to 2.3) for males and 1.1% (95% CI = 1.0 to 1.1) for females. Regression models showed increases in cancer risk with increasing platelet count, adjusted for sex, age, and smoking status (Table 1).
Figure 2 displays the one-year cancer incidences by age of patients in the high-normal and lower-normal groups, along with incidence rates recorded by NCRAS in England in 2016 (when NCRAS was formed through the merger of the National Cancer Intelligence Network and the National Disease Registry ), divided by gender. The incidence increased with age for both males and females, although no subgroup of females exceeded the NICE risk threshold of 3%; For this reason, females were excluded from subsequent meta-analyses. However, for males, incidences were significantly higher for patients with high normal counts compared with low normal counts for all but the youngest age group.
Immune Thrombocytopenic Purpura (itp) Symptoms And Treatment
One-year incidence of all cancers (except non-melanoma skin cancers).
What cause high platelet count, cause of high platelet count, cause of decreased platelet count, cause of increase platelet count, high platelet count cause, most common cause of low platelet count, common cause of low platelet count, cause of low platelet count, common causes of high platelet count, cause of high platelet count in blood, cause of high platelet count in adults, what is the most common cause of low platelet count